Compare Stocks: CTMX, RXRX, VRDN, and VERA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.47 -3.1%	$3.16	$2.43 ▼ $8.21	$555.64M	2.21	4.09 million shs	4.50 million shs
RXRX Recursion Pharmaceuticals	$3.95 -7.5%	$3.54	$2.77 ▼ $7.18	$2.29B	1.04	27.48 million shs	30.82 million shs
VERA Vera Therapeutics	$29.73 -1.7%	$32.79	$23.05 ▼ $56.05	$2.18B	1.06	2.70 million shs	1.73 million shs
VRDN Viridian Therapeutics	$18.34 +0.3%	$21.93	$13.18 ▼ $34.29	$2.07B	1.11	1.94 million shs	2.44 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	-3.14%	-6.08%	-32.33%	-34.31%	-26.71%
RXRX Recursion Pharmaceuticals	-7.49%	-2.95%	+14.83%	+10.96%	-35.14%
VERA Vera Therapeutics	-1.72%	-4.07%	-15.73%	-29.21%	-2.52%
VRDN Viridian Therapeutics	+0.33%	-3.42%	-20.85%	-7.09%	-14.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.47 -3.1%	$3.16	$2.43 ▼ $8.21	$555.64M	2.21	4.09 million shs	4.50 million shs
RXRX Recursion Pharmaceuticals	$3.95 -7.5%	$3.54	$2.77 ▼ $7.18	$2.29B	1.04	27.48 million shs	30.82 million shs
VERA Vera Therapeutics	$29.73 -1.7%	$32.79	$23.05 ▼ $56.05	$2.18B	1.06	2.70 million shs	1.73 million shs
VRDN Viridian Therapeutics	$18.34 +0.3%	$21.93	$13.18 ▼ $34.29	$2.07B	1.11	1.94 million shs	2.44 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	-3.14%	-6.08%	-32.33%	-34.31%	-26.71%
RXRX Recursion Pharmaceuticals	-7.49%	-2.95%	+14.83%	+10.96%	-35.14%
VERA Vera Therapeutics	-1.72%	-4.07%	-15.73%	-29.21%	-2.52%
VRDN Viridian Therapeutics	+0.33%	-3.42%	-20.85%	-7.09%	-14.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	381.78% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.06	104.05% Upside
VERA Vera Therapeutics	2.86	Moderate Buy	$80.15	169.61% Upside
VRDN Viridian Therapeutics	2.85	Moderate Buy	$38.69	110.97% Upside

Current Analyst Ratings Breakdown

Latest CTMX, RXRX, VRDN, and VERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
9/15/2026	VERA Vera Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/15/2026	VERA Vera Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy
9/14/2026	VRDN Viridian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/11/2026	CTMX CytomX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/8/2026	VERA Vera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$76.00 ➝ $83.00
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.30
8/17/2026	VERA Vera Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$34.00
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00
8/12/2026	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$125.00 ➝ $90.00

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$18.30M	29.41	N/A	N/A	$0.58 per share	4.26
RXRX Recursion Pharmaceuticals	$74.68M	28.32	N/A	N/A	$2.14 per share	1.85
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$8.48 per share	N/A
VRDN Viridian Therapeutics	$70.85M	29.33	N/A	N/A	$6.18 per share	2.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.04	N/A	N/A	N/A	-945.94%	-50.41%	-38.25%	11/4/2026 (Estimated)
VERA Vera Therapeutics	-$299.61M	-$5.86	N/A	N/A	N/A	N/A	-84.13%	-66.79%	11/4/2026 (Estimated)
VRDN Viridian Therapeutics	-$342.60M	-$3.37	N/A	N/A	N/A	-505.86%	-72.97%	-42.80%	11/4/2026 (Estimated)

Latest CTMX, RXRX, VRDN, and VERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	CTMX CytomX Therapeutics	-$0.09	N/A	N/A	N/A	$10.43 million	N/A
11/4/2026	Q3 2026	RXRX Recursion Pharmaceuticals	-$0.24	N/A	N/A	N/A	$12.98 million	N/A
11/4/2026	Q3 2026	VERA Vera Therapeutics	-$1.6092	N/A	N/A	N/A	$4.28 million	N/A
11/4/2026	Q3 2026	VRDN Viridian Therapeutics	-$0.9852	N/A	N/A	N/A	$4.58 million	N/A
8/10/2026	Q2 2026	VERA Vera Therapeutics	-$1.58	-$1.52	+$0.06	-$1.52	$1.28 million	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
8/6/2026	Q2 2026	VRDN Viridian Therapeutics	-$1.03	-$1.05	-$0.02	-$1.05	$0.06 million	$0.28 million
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	9.36	9.36
RXRX Recursion Pharmaceuticals	0.01	5.03	5.03
VERA Vera Therapeutics	0.18	10.92	10.92
VRDN Viridian Therapeutics	0.43	16.95	16.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
RXRX Recursion Pharmaceuticals	89.06%
VERA Vera Therapeutics	99.21%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	3.80%
RXRX Recursion Pharmaceuticals	6.65%
VERA Vera Therapeutics	15.90%
VRDN Viridian Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	69	217.90 million	209.62 million	Optionable
RXRX Recursion Pharmaceuticals	600	535.34 million	499.74 million	Optionable
VERA Vera Therapeutics	361	72.06 million	60.61 million	Optionable
VRDN Viridian Therapeutics	252	113.29 million	110.57 million	Optionable

CTMX, RXRX, VRDN, and VERA Headlines

Recent News About These Companies

Viridian Therapeutics (NASDAQ:VRDN) versus Revolution Medicines (NASDAQ:RVMD) Financial Contrast

October 7 at 4:15 AM | americanbankingnews.com

Emergent Biosolutions (NYSE:EBS) and Viridian Therapeutics (NASDAQ:VRDN) Head to Head Contrast

October 4, 2026 | americanbankingnews.com

Wall Street Zen Downgrades Viridian Therapeutics (NASDAQ:VRDN) to Strong Sell

October 4, 2026 | americanbankingnews.com

Viridian Therapeutics (NASDAQ:VRDN) Stock Dropped to Strong Sell by Wall Street Zen

October 4, 2026 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 5.8% - Here's Why

October 1, 2026 | marketbeat.com

Viridian Therapeutics stock weighs Lumvoa uptake against losses

September 30, 2026 | ad-hoc-news.deA

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 30, 2026 | americanbankingnews.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

September 30, 2026 | marketbeat.com

Wall Street Zen Upgrades Viridian Therapeutics (NASDAQ:VRDN) to "Sell"

September 26, 2026 | marketbeat.com

Bank of America Corp DE Makes New $17.35 Million Investment in Viridian Therapeutics, Inc. $VRDN

September 25, 2026 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)

September 23, 2026 | theglobeandmail.com

Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says

September 22, 2026 | finance.yahoo.com

Viridian Therapeutics: Two Products, One Commercial Buildout

September 17, 2026 | seekingalpha.com

Squarepoint Ops LLC Purchases 133,046 Shares of Viridian Therapeutics, Inc. $VRDN

September 13, 2026 | marketbeat.com

Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main

September 8, 2026 | globenewswire.com

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 2, 2026 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

August 26, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)

August 21, 2026 | theglobeandmail.com

Insider Selling: Viridian Therapeutics (NASDAQ:VRDN) Insider Sells 14,212 Shares

August 21, 2026 | insidertrades.com

Viridian Therapeutics Inc VRDN

August 15, 2026 | morningstar.comM

Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital

August 8, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX, RXRX, VRDN, and VERA Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.47 -0.08 (-3.14%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$2.48 +0.00 (+0.20%)

As of 04:15 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.95 -0.32 (-7.49%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$3.99 +0.04 (+1.06%)

As of 04:40 AM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Vera Therapeutics NASDAQ:VERA

$29.73 -0.52 (-1.72%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$29.54 -0.19 (-0.64%)

As of 04:08 AM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Viridian Therapeutics NASDAQ:VRDN

$18.34 +0.06 (+0.33%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$18.34 0.00 (0.00%)

As of 10/8/2026 07:30 PM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTMX, RXRX, VRDN, and VERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTMX, RXRX, VRDN, and VERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTMX, RXRX, VRDN, and VERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX, RXRX, VRDN, and VERA Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Recursion Pharmaceuticals NASDAQ:RXRX

Vera Therapeutics NASDAQ:VERA

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTMX, RXRX, VRDN, and VERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTMX, RXRX, VRDN, and VERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTMX, RXRX, VRDN, and VERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX, RXRX, VRDN, and VERA Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

Recursion Pharmaceuticals NASDAQ:RXRX

Vera Therapeutics NASDAQ:VERA

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools